Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic...

Area of Science:

• Nanotechnology
• Immunology
• Genetics

Background:

• Targeting the programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) pathway is a key cancer immunotherapy strategy.
• The tumor microenvironment (TME) plays a critical role in immune evasion and tumor progression.

Purpose of the Study:

• To develop and evaluate novel immune checkpoint inhibitor spherical nucleic acid (IC-SNA) nanoparticles for disrupting PD-1/PD-L1 signaling.
• To assess the efficacy of IC-SNAs in silencing PD-L1 expression and enhancing anti-tumor immunity in a preclinical cancer model.

Main Methods:

• Design and synthesis of IC-SNAs incorporating antisense DNA against PD-L1.
• In vitro assessment of IC-SNAs in MC38 colon cancer cells for PD-L1 silencing.
• Peritumoral administration of IC-SNAs in a syngeneic MC38 colon cancer mouse model.
• Analysis of PD-L1 expression, immune cell infiltration (CD8+ T cells), and tumor growth.

Main Results:

• IC-SNAs demonstrated concentration-dependent silencing of both surface and total PD-L1 in cancer cells.
• Peritumoral IC-SNA treatment reduced PD-L1 expression in tumor cells, dendritic cells, and myeloid-derived suppressor cells within the TME.
• Treatment led to increased CD8+ T cell accumulation and functionality, inhibited tumor growth, and extended animal survival.

Conclusions:

• IC-SNA nanoconstructs effectively disrupt PD-1/PD-L1 signaling through gene regulation within the TME.
• This novel nanomedicine approach shows significant potential as a cancer immunotherapy strategy.